drugset / Trial / NCT01463215
Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
NaSingle-groupOpen-labelTreatment
Summary
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-12
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambroxol | Small molecule | 187.5 mg | Oral |
| Subject | Ambroxol | Small molecule | 225 mg | Oral |